Using targeted therapies to treat uterine serous carcinoma
Targeting uterine serous carcinoma with antibody-drug conjugates
['FUNDING_OTHER'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-11124339
This study is looking at new treatments for uterine serous carcinoma, an aggressive type of cancer, by using special drugs that target the cancer cells, and it aims to find the best ways to make these treatments work even better for patients like you.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11124339 on ClinicalTrials.gov |
What this research studies
This research focuses on developing antibody-drug conjugates (ADCs) as a treatment for uterine serous carcinoma (USC), a type of aggressive cancer. The project aims to identify specific targets within USC tissues that can be effectively treated with these novel therapies. Researchers will analyze tissue samples to understand the expression of these targets and test the effectiveness of ADCs in laboratory models. By combining these therapies with other agents, they hope to enhance treatment outcomes for patients with USC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with uterine serous carcinoma who may benefit from targeted cancer therapies.
Not a fit: Patients with other types of cancer or those without uterine serous carcinoma may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with uterine serous carcinoma.
How similar studies have performed: Previous research has shown promising results with antibody-drug conjugates in treating various solid tumors, indicating potential success for this approach in USC.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SOOD, ANIL K — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: SOOD, ANIL K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents